Alison Bossis

Clinical Researcher

Data updated

Papers

8 publications

Trials

0 clinical trials

Research Footprint

Alison Bossis appears in 8 tracked papers (2013–2026), most studied alongside Psilocybin, across Depressive Disorders, Anxiety Disorders and Palliative & End-of-Life Distress.

Most-cited paper: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial (1678 citations).

Frequent co-authors: Gabrielle Agin-Liebes, James Guss and Stephen Ross.

Background & Research

Alison P. Bossis is a clinical researcher specialising in the therapeutic application of classic serotonergic psychedelics, particularly psilocybin, for psychiatric and existential distress associated with life‑threatening illness. Her work emphasises both clinical outcomes and the subjective, spiritual and meaning‑making dimensions of psychedelic experiences. Bossis has contributed to multiple papers and clinical follow‑ups examining acute and sustained reductions in depression, anxiety, loss of meaning and suicidal ideation after psilocybin‑assisted psychotherapy in patients with cancer, as well as detailed qualitative case reports of individual patient experiences.

Her research portfolio includes mixed‑methods investigations of patient narratives, long‑term follow‑up assessments and studies of changes in religious and spiritual attitudes among clergy and other participants following psilocybin administration. Through these contributions, Bossis has helped characterise the phenomenology of therapeutic psychedelic sessions, the durability of clinical benefit in life‑threatening illness, and the interplay between existential concerns, spirituality and symptom change, informing clinical protocols and hypotheses for mechanisms of change in psychedelic‑assisted therapy.